Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Gore

Showing results (181-190 of 306) with videos related to

Pageof 31
Sort By:
Haematologica|October 2, 2009
A phase 2 study of vorinostat in acute myeloid leukemiaEric W Schaefer, Arturo Loaiza-Bonilla, Mark Juckett, et al.
Cancer|August 6, 2019
Underutilization of guideline-recommended supportive care among older adults with multiple myeloma in the United StatesSmith Giri, Weiwei Zhu, Rong Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2017
Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of LifeRong Wang, Amer M Zeidan, Stephanie Halene, et al.
Cancer|June 10, 2011
Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromesLewis R Silverman, Pierre Fenaux, Ghulam J Mufti, et al.
Blood|November 23, 2000
Evaluation of Apaf-1 and procaspases-2, -3, -7, -8, and -9 as potential prognostic markers in acute leukemiaP A Svingen, J E Karp, S Krajewski, et al.
British Journal of Haematology|September 12, 1998
Inhibited apoptosis and drug resistance in acute myeloid leukaemiaB D Smith, B J Bambach, M S Vala, et al.
Oncotarget|February 11, 2017
Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapyThomas Prebet, Andrea Toma, Thomas Cluzeau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1994
Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemiaE K Rowinsky, A Adjei, R C Donehower, et al.
European Journal of Haematology|April 17, 2010
Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*Valeria Santini, Pierre Fenaux, Ghulam J Mufti, et al.
Annals of Hematology|July 30, 2016
Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemiaTae Kon Kim, Mina L Xu, Nikolai A Podoltsev, et al.
Pageof 31

Showing results (181-190 of 306) with videos related to

Sort By:
Pageof 31
Haematologica|October 2, 2009
A phase 2 study of vorinostat in acute myeloid leukemiaEric W Schaefer, Arturo Loaiza-Bonilla, Mark Juckett, et al.
Cancer|August 6, 2019
Underutilization of guideline-recommended supportive care among older adults with multiple myeloma in the United StatesSmith Giri, Weiwei Zhu, Rong Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2017
Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of LifeRong Wang, Amer M Zeidan, Stephanie Halene, et al.
Cancer|June 10, 2011
Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromesLewis R Silverman, Pierre Fenaux, Ghulam J Mufti, et al.
Blood|November 23, 2000
Evaluation of Apaf-1 and procaspases-2, -3, -7, -8, and -9 as potential prognostic markers in acute leukemiaP A Svingen, J E Karp, S Krajewski, et al.
British Journal of Haematology|September 12, 1998
Inhibited apoptosis and drug resistance in acute myeloid leukaemiaB D Smith, B J Bambach, M S Vala, et al.
Oncotarget|February 11, 2017
Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapyThomas Prebet, Andrea Toma, Thomas Cluzeau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1994
Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemiaE K Rowinsky, A Adjei, R C Donehower, et al.
European Journal of Haematology|April 17, 2010
Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*Valeria Santini, Pierre Fenaux, Ghulam J Mufti, et al.
Annals of Hematology|July 30, 2016
Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemiaTae Kon Kim, Mina L Xu, Nikolai A Podoltsev, et al.
Pageof 31